• Grifols' November 2, 2026, third-quarter earnings call featured CEO Nacho Abia, CFO Rahul Srinivasan and investor relations head Daniel Segarra.
• Quarterly adjusted EBITDA reached EUR 538 million; management maintained its full-year adjusted EBITDA margin target of 25%.
• Biopharma growth should moderate in the fourth quarter, reflecting sales timing benefits and a strong year-earlier comparison.
• China's albumin recovery is taking longer than expected; elevated inventories continue to pressure sales despite early improvement in end-market demand.
• Srinivasan expects no update on the potential US Biopharma IPO until 2027, with the board continuing its assessment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grifols SA published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.